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Testicular cancer (TC) is the most common neoplasm in males aged 15–40 years. The majority of patients have no evi-
dence of metastases at diagnosis and thus have clinical stage I (CSI) disease [Oldenburg J, Fossa SD, Nuver J et al.
Testicular seminoma and non-seminoma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann
Oncol 2013; 24(Suppl 6): vi125–vi132; de Wit R, Fizazi K. Controversies in the management of clinical stage I testis
cancer. J Clin Oncol 2006; 24: 5482–5492.]. Management of CSI TC is controversial and options include surveillance
and active treatment. Different forms of adjuvant therapy exist, including either one or two cycles of carboplatin chemo-
therapy or radiotherapy for seminoma and either one or two cycles of cisplatin-based chemotherapy or retroperitoneal
lymph node dissection for non-seminoma. Long-term disease-speciﬁc survival is ∼99% with any of these approaches, in-
cluding surveillance. While surveillance allows most patients to avoid additional treatment, adjuvant therapy markedly
lowers the relapse rate. Weighing the net beneﬁts of surveillance against those of adjuvant treatment depends on prioritiz-
ing competing aims such as avoiding unnecessary treatment, avoiding more burdensome treatment with salvage chemo-
therapy and minimizing the anxiety, stress and life disruption associated with relapse. Unbiased information about the
advantages and disadvantages of surveillance and adjuvant treatment is a prerequisite for informed consent by the
patient. In a clinical scenario like CSI TC, where different disease-management options produce indistinguishable long-
term survival rates, patient values, priorities and preferences should be taken into account. In this review, we provide an
overview about risk factors for relapse, potential beneﬁts and harms of adjuvant chemotherapy and active surveillance
and a rationale for involving patients in individualized decision making about their treatment rather than adopting a uniform
recommendation for all.
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introduction
Testicular cancer (TC) is the most common neoplasm in young
males aged between 15 and 40 years, and the majority of
patients are diagnosed with clinical stage I (CSI) disease,
meaning that they have no evidence of regional or distant me-
tastases [1, 2]. Active surveillance (AS) is an option for CSI TC
patients, but the authors of this article are not convinced that
‘most CSI TC patients should be encouraged toward AS as
primary management’ as recently proposed by Nichols et al. [3]
Rather, each patient should be informed about the potential
advantages and disadvantages of AS and adjuvant chemother-
apy (ACT) as a prerequisite for obtaining informed consent for
either. Here, we present our arguments for a personalized ap-
proach to management [4].
seminoma
About 80%–85% of patients with seminoma are diagnosed with
CSI and ∼16% relapse during AS [5]. Enthusiasm for adjuvant
radiotherapy has been tempered by the risk of radiation-
induced secondary cancers and most European guidelines have
removed this treatment option [1, 6]. Tumor size >4 cm and in-
vasion of the rete testis were associated with an increased risk of
relapse in an international retrospective study of 638 men,
reporting relapse rates of 31.5%, 15.9% and 12% in those with
both, one and neither risk factor, respectively [7]. Some subse-
quent reports questioned these ﬁndings [5, 8], but more recent-
ly, SWENOTECA reported that the presence of either risk factor
independently increases the risk of relapse during AS signiﬁ-
cantly [9]. SWENOTECA reported a relapse rate of 2.9% in
patients without risk factors compared with 21.7% in patients
with 1–2 risk factors, although the number of men with two risk
factors who were managed with surveillance was too small to
assess whether their risk of relapse was higher than those with
only one [9]. There are thus abundant data conﬁrming our
ability to identify low- and intermediate-risk patients, but fewer
than one-third of the ‘high-risk’ patients are expected to relapse
if managed with surveillance. For patients weighing AS versus
ACT, knowing our best estimate of their risk of relapse is critical
for them to be able to make an informed decision.
A single cycle of adjuvant carboplatin (AUC7) has been estab-
lished as effective ACT when compared with adjuvant radiother-
apy in the largest TC phase III trial ever reported. Relapse rates
were similar, but carboplatin resulted in fewer adverse effects,
less sick-leave and a signiﬁcant reduction in contralateral tes-
ticular tumors [10, 11]. Relapse rates after a single dose of adju-
vant carboplatin in unselected populations are 4%, translating
into a 75% relapse reduction [5], which is acceptable to many
patients given the low risk of complications. The prospect of a
single infusion with a high chance of being able to work shortly
thereafter is appealing to many patients and unique in cancer
treatment. There is, however, skepticism against carboplatin,
mainly in the USA, where adjuvant radiotherapy still is consid-
ered a viable option for CSI seminoma [12]. In numerous
studies, two cycles of carboplatin reduced the relapse rate to
0%–3%, translating into an average relapse reduction of 90%,
but this approach has not been tested in a randomized, con-
trolled trial [10, 13, 14].
non-seminoma
About 55%–60% of patients with non-seminoma TC present
with CSI. Approximately 25%–30% relapse during AS. Relapse
rates depend on lympho-vascular invasion (LVI) in the pri-
mary tumor: 50% in LVI+ versus 15% in LVI− patients [15–17].
Thereby, most guidelines differentiate the treatment of high-
and low-risk patients based on LVI status. A predominance of
embryonal carcinoma in the primary tumor also appears to be
associated with an increased risk of relapse, but this variable has
been less well validated and appears to be a less powerful prog-
nostic factor [18].
Historically, retroperitoneal lymph node dissection (RPLND)
has been a standard treatment option, but given inferior out-
comes in a community-based, randomized trial [19], RPLND is
no longer regarded as standard in the community setting [1, 6].
RPLND is, however, associated with the lowest likelihood of re-
quiring systemic chemotherapy when carried out by highly
experienced surgeons. The downside of RPLND is that it is asso-
ciated with the highest likelihood of requiring more than one
treatment modality because of the number of patients who
receive chemotherapy after RPLND either for pathological stage
II disease discovered during the operation or for relapse.
ACT in stage I non-seminoma
ACT with two cycles of bleomycin, etoposide and cisplatin
(BEP) has been employed in many smaller series, but the two
largest studies used BEP × 1. In a randomized trial comparing
RPLND and BEP × 1, 191 patients received ACT with a reported
2-year relapse rate of 0.5% [19]. In a community-based pro-
spective study, high-risk patients were recommended BEP × 1,
whereas low-risk patients could choose between AS and BEP × 1
[20]. Relapse rates after a median follow-up of 7.9 years of 517
patients who received BEP × 1 were 1.6% and 3.2% for LVI−,
and LVI+ tumors, respectively, whereas relapse rates during sur-
veillance were 12% and 42% [17]. Thereby, ACT prevented
>90% of relapses. Importantly, no relapses were observed after
3.3 years. Results of a completed UK prospective trial, of
BEP × 1 in 246 high-risk patients, are eagerly awaited. Many
European experts consider BEP × 1 as the new standard ACT
for non-seminoma, since reducing BEP to one cycle is expected
to improve the risk–beneﬁt ratio considerably.
burden of intervention
Quantifying the overall ‘treatment burden’ can be helpful for de-
cision making (Table 1). As an example, 100 LVI+ patients
managed with AS will receive ∼150 cycles of BEP, as ∼50% will
relapse, requiring minimum BEP × 3 with additional RPLND in
those with residual lesions. BEP × 1 for 100 patients equals 100
cycles of BEP, and subsequently approximately nine additional
BEP cycles for ∼3 (3.2%) relapsing patients, adding up to a total
of 109 cycles of BEP. Furthermore, only three men treated with
AC will end up needing a full course of 3–4 cycles of chemother-
apy, compared with 50 high-risk men undergoing AS (Table 1).
Thus, while both the short and long-term toxicities of chemo-
therapy must be taken into consideration when making treat-
ment decisions, administering ACT to patients LVI reduces the
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overall chemotherapy exposure in this population. Also, RPLND
might be necessary in as many as 26% of patients relapsing
during AS [21]. This number is higher than that reported by
SWENOTECA, where 7.7% of AS patients required RPND as
opposed to 2.2% after ACT [20]. Nevertheless, these numbers
favor ACT both with regard to chemotherapy and surgery [22].
The ﬁnancial costs of managing non-seminoma CSI have been
calculated by Link et al. [23] who concluded that ACT is cost ef-
fective over AS or RPLND in LVI+ non-seminoma CSI patients.
Of note, these calculations were based on BEP × 2, suggesting an
even bigger advantage of BEP × 1.
toxicity related to ACT versus relapse
treatment
Treatment-related toxicity is crucial considering survival rates of
99%–100% regardless of treatment strategy. So far, there is little
indication that adjuvant carboplatin is associated with serious
late toxicities [24]. Admittedly, long-term data exceeding 15 years
are lacking. Most serum parameters as well as lung function,
audiometry, sexual function and fertility rates seem to be un-
affected by adjuvant treatment with 1–2 cycles of BEP, although
the numbers are small and observation time is too short for de-
ﬁnitive conclusions [25–27].
Relapse treatment is, however, associated with considerable
long-term toxicity including serious late effects like cardiovascu-
lar disease and second cancers [28]. Of note, acute toxicity
is also an issue following chemotherapy for metastatic disease:
the single death from acute toxicity among 745 CSI patients in
the SWENOTECA report was initially managed by AS, relapsed,
and then received four cycles of BEP with subsequent brain
herniation secondary to a stroke 1 week after the last cycle [20].
A clear dose–relationship has been established for the following
BEP sequelae: pulmonary toxicity, fertility, neurotoxicity, oto-
toxicity, nephrotoxicity, metabolic syndrome and hypogonad-
ism [29–35]. Considering these well-known toxicities after
BEP × 3–4, it appears reasonable to administer ACT to reduce
the risk of relapse and thereby limit the proportion of patients
requiring such extensive chemotherapy. However, we do not
recommend administering ACT to all CSI TC patients. Instead,
we favor discussing the advantages and disadvantages of this
option as well as those of AS. The use of AS, thus avoiding
unnecessary chemotherapy in the majority of patients, is very
appealing. However, there are challenges to this approach.
challenges of AS
Potential disadvantages of AS include secondary malignancies
from ionizing radiation from imaging studies, non-adherence to
the surveillance schedule and consequent presentation with
poor-risk disease, the toxicity of 3–4 cycles of BEP, resection of
residual masses and the life disruption associated with relapse.
Radiation exposure by frequent CT examinations during AS is a
concern in patients with cure rates approaching 100% [36].
Imaging by MRI avoids this risk, but is unavailable for the ma-
jority of patients worldwide. However, radiologic follow-up of
TC patients in Sweden and Norway is based on MRI with excel-
lent results [5, 17, 37]. Lifetime cancer attributable to CT exami-
nations for patients with CSI non-seminoma has been calculated
to range from 1 in 52 (1.9%) to 1 in 63 (1.2%), depending on
age [38]. It is not currently possible to substantiate the risk of
cancer induction by radiation exposure, but it is certainly not
zero and radiation exposure can be reduced if ACT is chosen
rather than AS according to the guidelines from the National
Comprehensive Cancer Network (NCCN) or the Royal
Marsden Hospital, London (Table 2) [39].
Successful AS requires adherence to the follow-up schedule,
but a signiﬁcant proportion of patients do not adhere to recom-
mended follow-up [41]. Excellent outcomes for AS are reported
by countries with a well-funded public healthcare system, e.g.
Scandinavian countries and Canada. However, except from the
work by Nichols et al. who cooperates with Canadian institu-
tions, there are no United States-based reports on long-term
outcomes or adherence with AS. Thereby, data from Yu et al.
assessing adherence rates by insurance claims are of particular
interest: 29% of patients were not assessed for recurrence at all.
Adherence to follow-up declined with time, and only 45% of
patients underwent abdominal imaging during later years of AS
[42]. A Canadian series reported a mean rate of ‘compliance’
with CT scanning of only 64% (range 32.2%–100%) [43]. ‘Lost
to follow-up’ is unfortunately an all too frequent status among
the young and mobile CSI TC patients [44].
Low adherence was presumably the reason for the poor sur-
vival of only 90% of 145 CSI non-seminoma patients, managed
at the Slovakian center in Bratislava from 1984 to 1991 with AS
Table 1. Estimated use of BEP cycles for different scenarios of AS
versus adjuvant BEP × 1 in relation to vascular invasion
All VI+ VI−
AS ACT AS ACT AS ACT
No. of patients 100 100 100 100 100 100
Relapses 25 2 50 3 15 2
No. of BEP cycles 75 106 150 109 45 106
Salvage treatment = 3–4 × BEP ± surgery.
VI, vascular invasion; +, present; −, absent; AS, active surveillance;
ACT, adjuvant chemotherapy (BEP × 1); BEP, bleomycin, etoposide
and cisplatin.
Table 2. Number of CT scans required for CSI TC during AS or
after ACT
Seminoma Non-
seminoma
AS ACT AS ACT
Royal Marsden Hospital [39] 7 3 3 1
NCCN [40] 7–8 3 8–12 6–7
CSI, clinical stage I; TC, testicular cancer; AS, active surveillance;
ACT, adjuvant chemotherapy; NCCN, National Comprehensive
Cancer Network.
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independent of LVI status: 52 of 145 (36%) patients experienced
a relapse, and 15 of these (29%) died from TC [45]. Admittedly,
these ﬁgures may not apply for contemporary patients managed
in European or American centers, but the follow-up protocol
was standardized, including repeated CT imaging and relapse
treatment comprised cisplatin-based chemotherapy. This center
applied a risk-based treatment from 1992 onwards with AS
reserved for LV− patients only, whereas LVI+ patients received
ACT with BEP × 2. Subsequently, only 2 of 111 (1.9%) LVI+
patients relapsed and neither of them died [45].
Patients may experience increased anxiety before follow-up
visits over many years. Fear of relapse has been reported by ap-
proximately one of three long-term survivors 10 years after suc-
cessful treatment [46]. Personality qualities like coping ability
and level of distress are important factors for fear of relapse and
should be incorporated into decision making in CSI TC.
The resulting disruption of normal life by recurrence during
AS, necessitating 9–12 weeks of intensive chemotherapy and
possibly surgery at an unplanned time point, is likely to be par-
ticularly damaging for adolescent and young adult males who
are establishing their lives as the diagnosis of metastatic disease
sets almost all activities including work and education at an
abrupt halt. In contrast, if ACT is chosen as elective therapy, the
likelihood of having their life interrupted again—after the time
of diagnosis—is reduced to <4%. This peace of mind is of con-
siderable value for some individuals and might have contributed
to the following results: in a British study, patients tended to opt
for AS if the risk of recurrence was <30%, while the majority
opted for ACT if the risk approximated 50%. Importantly, there
was wide variation among apparently similar groups [47]. These
ﬁgures pertain to BEP × 2 as ACT and BEP × 4 as treatment of
recurrence. Probably, a greater proportion of patients would
have chosen ACT if BEP × 1 had been an option. These ﬁgures
help to estimate the threshold level for the overall cohort of
patients. The individual threshold for choosing ACT or AS,
however, may be different, and is inﬂuenced by psychological
factors such as personal risk aversion.
unbiased information
Providing unbiased information is essential and is mandated by
the ethical mandate to respect patient autonomy, which is
deﬁned as ‘the right of patients to make decisions about their
medical care without their health care provider trying to inﬂu-
ence the decision. Patient autonomy does allow for health care
providers to educate the patient but does not allow the health
care provider to make the decision for the patient’[48].
The following statement by Nichols et al. [3] may infringe the
principle of patient autonomy and unbiased information:
‘Clinical outcomes using a broad policy of active surveillance for
clinical stage I testicular cancer are unsurpassed by management
strategies that rely on adjuvant therapies’. We consider this
statement to be biased in favor of AS since there are no trials
comparing AS with ACT allowing this conclusion to be drawn.
Intriguingly, it has equal veracity when the terms ‘active surveil-
lance’ and ‘adjuvant therapies’ are switched.
Open and honest communication about all management
options may contribute to achieving an effective doctor–patient
relationship, which has been shown to predict adherence to
follow-up schedules [41]. The authors of the ‘Prospective Study
of Factors Predicting Adherence to Medical Advice in Men
With Testicular Cancer’ did conclude that ‘Patients who per-
ceived an unsatisfactory affective relationship with their clinician
that included an inability to trust the clinician and a perception
that they were not being treated as “a person” were subsequently
more likely to disregard medical advice regarding follow-up’.
The most relevant way of personalizing management of CSI TC
is the presentation and appraisal of risk factors and their impli-
cations on the potential beneﬁt of ACT versus AS.
In their editorial on the risk-adapted management of non-
seminoma CSI by SWENOTECA, which recommends ACT to
patients with LVI+, and leaves the decision between AS and
ACT to LVI− patients, Nichols and Kollmannsberger [49] have
expressed their skepticism toward patient autonomy: ‘Is patient
autonomy in treatment decisions a good thing, or does it just
shift the burden of the wrong choice to the patient with asso-
ciated remorse and guilt?’ However, both AS and ACT for CSI
TC result in nearly 100% long-term disease-speciﬁc survival and
neither has been shown to result in superior quality of life, so it
is unclear how either option could be considered ‘wrong’.
Moreover, what is right for one patient may not be for the next.
Most patients appreciate comprehensive information and accept
uncertainty and are willing to contribute to decision making
about their own health. We therefore refute attempts to ‘protect’
them from this uncertainty by patronizing them and denying
them self-determination. Allowing patients to decide on either
ACT or AS according to their own preferences gives empower-
ment and respects them as self-determining individuals; this, in
turn, strengthens the therapeutic relationship and can increase
adherence with either self-chosen approach.
A recent decision analysis revealed that quality-adjusted sur-
vival was similar for AS, ACT and RPLND. Adjuvant treatment
was favored when the risk of recurrence was 37% or higher [50].
Of note, in the absence of reliable long-term assessment, toxicity
data after BEP × 3 were presented instead of BEP × 1, thereby
overestimating ACT’s toxicity. Furthermore, the complications
of AS might have been underestimated since up to one of four
relapsing patients requires post-chemotherapy RPLND and
5.4% have intermediate or even poor prognosis according to
IGCCCG [21].
Within SWENOTECA, 93% of the LVI+, and approximately
1 in 3 LVI−, patients received ACT, with the remainder follow-
ing AS [20]. Within the British Columbia Cancer Agency or the
Oregon Testis Cancer Program both of which follow a non-
risk-adapted surveillance program, 223 of 233 (95%) CSI non-
seminoma patients did opt for AS, including 60 LVI+ patients,
of whom 30 (50%) experienced a relapse [18]. The reasons for
this diametrically different pattern of choice of LVI+ patients are
possibly not based on different risk perceptions by the patients,
but rather varying risk presentation by the physicians.
Few, if any, situations within oncology are characterized by
such a high degree of clinical equipoise between the alternatives,
e.g. AS versus ACT for CSI TC [51]. Clinical equipoise, deﬁned
‘as genuine uncertainty within the expert medical community
about the preferred treatment’ is considered an ethical require-
ment for randomized trials, and mandates in the setting of TC
CSI unbiased information about the beneﬁts and risks of each al-
ternative in order to let the patient reach an individual decision.
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conclusion
We encourage tailoring management of CSI TC according to
the patient’s individual risks and his individual interpretation of
these risks. Many patients consider ACT a lesser evil than the
prospect of frequent follow-up visits with the risk of requiring
BEP × 3–4 at an unplanned time point plus potential additional
surgery. The reported low adherence to AS protocols could indi-
cate an evasion strategy by a substantial proportion of patients
and dealing with their TC with ACT might be safer. Considering
very similar outcomes of AS and ACT, individual patient pre-
ferences should be a strong factor in management decision.
Therefore, we believe in:
(1) Identifying the patient’s individual risks and preferences,
(2) Involving the patient in a discussion about the potential
trade-offs of the different management strategies and
(3) Helping the patient in deciding which management suits
him.
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Available evidence and new biological perspectives on
medical treatment of advanced thymic epithelial tumors
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Thymic epithelial tumors (TETs) are rare primary mediastinal tumors arising from thymic epithelium. Their rarity and com-
plexity hinder investigations of their causes and therapy development. Here, we summarize the existing knowledge
regarding medical treatment of these tumors, and thoroughly review the known genetic aberrations associated with TETs
and the present status of potential biological treatments. Epidermal growth factor receptor (EGFR), stem-cell factor recep-
tor, insulin-like growth factor-1 receptor (IGF1R), and vascular endothelial growth factors (VEGF-A, VEGF-B, and VEGF-2)
are overexpressed in TETs. EGFR overexpression in TETs is associated with higher stage, and IGF1R overexpression has
poor prognostic value. Data indicate that anti-IGF1R monoclonal antibodies, and inhibitors of angiogenesis, somatostatin
receptors, histone deacetylase, mammalian target of rapamycin, and cyclin-dependent kinases may be active against
TETs. Continued investigations in this ﬁeld could lead to advancement of targeted and biological therapies for TETs.
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